No profile data available.
Metsera, Inc. (MTSR) is a healthcare company in the obesity treatment pharmaceuticals industry, based in New York, United States, with about 125 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$209.13 million. In Q2 2025 (the quarter ended June 30, 2025) revenue was $0. Its market capitalization was $7.43 billion as of November 13, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of November 13, 2025.
, a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases.
Metsera reported $0 in revenue for fiscal year 2024. In Q2 2025 revenue was $0.
$7.43 billion as of November 13, 2025.
Listed companies of a similar size in the same industry (obesity treatment pharmaceuticals) include Rhythm Pharmaceuticals, Inc. (RYTM), Structure Therapeutics Inc. (GPCR), BioAge Labs, Inc. (BIOA), Aardvark Therapeutics, Inc. (AARD).